171 related articles for article (PubMed ID: 38386699)
1. Selective DRD2 antagonist and ClpP agonist ONC201 in a recurrent non-midline H3 K27M-mutant glioma cohort.
Odia Y; Hall MD; Cloughesy TF; Wen PY; Arrillaga-Romany I; Daghistani D; Mehta MP; Tarapore RS; Ramage SC; Allen JE
Neuro Oncol; 2024 May; 26(Supplement_2):S165-S172. PubMed ID: 38386699
[TBL] [Abstract][Full Text] [Related]
2. Pediatric and adult H3 K27M-mutant diffuse midline glioma treated with the selective DRD2 antagonist ONC201.
Chi AS; Tarapore RS; Hall MD; Shonka N; Gardner S; Umemura Y; Sumrall A; Khatib Z; Mueller S; Kline C; Zaky W; Khatua S; Weathers SP; Odia Y; Niazi TN; Daghistani D; Cherrick I; Korones D; Karajannis MA; Kong XT; Minturn J; Waanders A; Arillaga-Romany I; Batchelor T; Wen PY; Merdinger K; Schalop L; Stogniew M; Allen JE; Oster W; Mehta MP
J Neurooncol; 2019 Oct; 145(1):97-105. PubMed ID: 31456142
[TBL] [Abstract][Full Text] [Related]
3. ONC201 (Dordaviprone) in Recurrent H3 K27M-Mutant Diffuse Midline Glioma.
Arrillaga-Romany I; Gardner SL; Odia Y; Aguilera D; Allen JE; Batchelor T; Butowski N; Chen C; Cloughesy T; Cluster A; de Groot J; Dixit KS; Graber JJ; Haggiagi AM; Harrison RA; Kheradpour A; Kilburn LB; Kurz SC; Lu G; MacDonald TJ; Mehta M; Melemed AS; Nghiemphu PL; Ramage SC; Shonka N; Sumrall A; Tarapore RS; Taylor L; Umemura Y; Wen PY
J Clin Oncol; 2024 May; 42(13):1542-1552. PubMed ID: 38335473
[TBL] [Abstract][Full Text] [Related]
4. ACTION: a randomized phase 3 study of ONC201 (dordaviprone) in patients with newly diagnosed H3 K27M-mutant diffuse glioma.
Arrillaga-Romany I; Lassman A; McGovern SL; Mueller S; Nabors B; van den Bent M; Vogelbaum MA; Allen JE; Melemed AS; Tarapore RS; Wen PY; Cloughesy T
Neuro Oncol; 2024 May; 26(Supplement_2):S173-S181. PubMed ID: 38445964
[TBL] [Abstract][Full Text] [Related]
5. Biological activity of weekly ONC201 in adult recurrent glioblastoma patients.
Arrillaga-Romany I; Odia Y; Prabhu VV; Tarapore RS; Merdinger K; Stogniew M; Oster W; Allen JE; Mehta M; Batchelor TT; Wen PY
Neuro Oncol; 2020 Jan; 22(1):94-102. PubMed ID: 31702782
[TBL] [Abstract][Full Text] [Related]
6. First clinical experience with DRD2/3 antagonist ONC201 in H3 K27M-mutant pediatric diffuse intrinsic pontine glioma: a case report.
Hall MD; Odia Y; Allen JE; Tarapore R; Khatib Z; Niazi TN; Daghistani D; Schalop L; Chi AS; Oster W; Mehta MP
J Neurosurg Pediatr; 2019 Apr; 23(6):719-725. PubMed ID: 30952114
[TBL] [Abstract][Full Text] [Related]
7. Diffuse high-grade gliomas with H3 K27M mutations carry a dismal prognosis independent of tumor location.
Karremann M; Gielen GH; Hoffmann M; Wiese M; Colditz N; Warmuth-Metz M; Bison B; Claviez A; van Vuurden DG; von Bueren AO; Gessi M; Kühnle I; Hans VH; Benesch M; Sturm D; Kortmann RD; Waha A; Pietsch T; Kramm CM
Neuro Oncol; 2018 Jan; 20(1):123-131. PubMed ID: 29016894
[TBL] [Abstract][Full Text] [Related]
8. Incidence and clinicopathologic features of H3 K27M mutations in adults with radiographically-determined midline gliomas.
Schreck KC; Ranjan S; Skorupan N; Bettegowda C; Eberhart CG; Ames HM; Holdhoff M
J Neurooncol; 2019 May; 143(1):87-93. PubMed ID: 30864101
[TBL] [Abstract][Full Text] [Related]
9. Transcriptomic and epigenetic profiling of 'diffuse midline gliomas, H3 K27M-mutant' discriminate two subgroups based on the type of histone H3 mutated and not supratentorial or infratentorial location.
Castel D; Philippe C; Kergrohen T; Sill M; Merlevede J; Barret E; Puget S; Sainte-Rose C; Kramm CM; Jones C; Varlet P; Pfister SM; Grill J; Jones DTW; Debily MA
Acta Neuropathol Commun; 2018 Nov; 6(1):117. PubMed ID: 30396367
[TBL] [Abstract][Full Text] [Related]
10. Diffusion Characteristics of Pediatric Diffuse Midline Gliomas with Histone H3-K27M Mutation Using Apparent Diffusion Coefficient Histogram Analysis.
Aboian MS; Tong E; Solomon DA; Kline C; Gautam A; Vardapetyan A; Tamrazi B; Li Y; Jordan CD; Felton E; Weinberg B; Braunstein S; Mueller S; Cha S
AJNR Am J Neuroradiol; 2019 Nov; 40(11):1804-1810. PubMed ID: 31694820
[TBL] [Abstract][Full Text] [Related]
11. Phase I dose escalation and expansion trial of single agent ONC201 in pediatric diffuse midline gliomas following radiotherapy.
Gardner SL; Tarapore RS; Allen J; McGovern SL; Zaky W; Odia Y; Daghistani D; Diaz Z; Hall MD; Khatib Z; Koschmann C; Cantor E; Kurokawa R; MacDonald TJ; Aguilera D; Vitanza NA; Mueller S; Kline C; Lu G; Allen JE; Khatua S
Neurooncol Adv; 2022; 4(1):vdac143. PubMed ID: 36382108
[TBL] [Abstract][Full Text] [Related]
12. Adult diffuse midline gliomas H3 K27-altered: review of a redefined entity.
López-Pérez CA; Franco-Mojica X; Villanueva-Gaona R; Díaz-Alba A; Rodríguez-Florido MA; Navarro VG
J Neurooncol; 2022 Jul; 158(3):369-378. PubMed ID: 35567713
[TBL] [Abstract][Full Text] [Related]
13. Panobinostat in adults with H3 K27M-mutant diffuse midline glioma: a single-center experience.
Neth BJ; Balakrishnan SN; Carabenciov ID; Uhm JH; Daniels DJ; Kizilbash SH; Ruff MW
J Neurooncol; 2022 Mar; 157(1):91-100. PubMed ID: 35076860
[TBL] [Abstract][Full Text] [Related]
14. Diffuse hemispheric glioma with H3 p.K28M (K27M) mutation: Unusual non-midline presentation of diffuse midline glioma, H3 K27M-altered?
Donev K; Sundararajan V; Johnson D; Balan J; Chambers M; Paulson VA; Scherpelz KP; Abdullaev Z; Quezado M; Cimino PJ; Pratt D; Valerio E; Alves de Castro JV; Carraro DM; Torrezan GT; Wolff BM; Kulikowski LD; Costa FD; Aldape K; Ida CM
J Neuropathol Exp Neurol; 2024 Apr; 83(5):357-364. PubMed ID: 38447592
[TBL] [Abstract][Full Text] [Related]
15. Characteristics of H3 K27M-mutant gliomas in adults.
Meyronet D; Esteban-Mader M; Bonnet C; Joly MO; Uro-Coste E; Amiel-Benouaich A; Forest F; Rousselot-Denis C; Burel-Vandenbos F; Bourg V; Guyotat J; Fenouil T; Jouvet A; Honnorat J; Ducray F
Neuro Oncol; 2017 Aug; 19(8):1127-1134. PubMed ID: 28201752
[TBL] [Abstract][Full Text] [Related]
16. Adult diffuse midline gliomas: Clinical, radiological, and genetic characteristics.
Dono A; Takayasu T; Ballester LY; Esquenazi Y
J Clin Neurosci; 2020 Dec; 82(Pt A):1-8. PubMed ID: 33317715
[TBL] [Abstract][Full Text] [Related]
17. A review of current therapeutics targeting the mitochondrial protease ClpP in diffuse midline glioma, H3 K27-altered.
Jackson ER; Persson ML; Fish CJ; Findlay IJ; Mueller S; Nazarian J; Hulleman E; van der Lugt J; Duchatel RJ; Dun MD
Neuro Oncol; 2024 May; 26(Supplement_2):S136-S154. PubMed ID: 37589388
[TBL] [Abstract][Full Text] [Related]
18. Noninvasive assessment of H3 K27M mutational status in diffuse midline gliomas by using apparent diffusion coefficient measurements.
Chen H; Hu W; He H; Yang Y; Wen G; Lv X
Eur J Radiol; 2019 May; 114():152-159. PubMed ID: 31005167
[TBL] [Abstract][Full Text] [Related]
19. Safety and pharmacokinetics of ONC201 (dordaviprone) administered two consecutive days per week in pediatric patients with H3 K27M-mutant glioma.
Odia Y; Koschmann C; Vitanza NA; de Blank P; Aguilera D; Allen J; Daghistani D; Hall M; Khatib Z; Kline C; MacDonald T; Mueller S; Faison SL; Allen JE; Naderer OJ; Ramage SC; Tarapore RS; McGovern SL; Khatua S; Zaky W; Gardner SL
Neuro Oncol; 2024 May; 26(Supplement_2):S155-S164. PubMed ID: 38400780
[TBL] [Abstract][Full Text] [Related]
20. H3 K27M-mutant diffuse midline gliomas in different anatomical locations.
Wang L; Li Z; Zhang M; Piao Y; Chen L; Liang H; Wei Y; Hu Z; Zhao L; Teng L; Lu D
Hum Pathol; 2018 Aug; 78():89-96. PubMed ID: 29727696
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
